Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Update on FDA Advisory Committee Vote on LYNPARZA Plus Abiraterone and Prednisone or Prednisolone in First-Line mCRPC.

Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer

Merck (MRK) beats Q1 estimates for earnings and sales. It raises its 2023 guidance.

Merck (MRK) Beats on Q1 Earnings and Sales, Ups 2023 View

Merck & Co., Inc. (MRK) Q1 2023 Earnings Call Transcript.

Merck & Co., Inc. (MRK) Q1 2023 Earnings Call Transcript

Merck & Co Inc (NYSE:MRK) has reported a decline in first-quarter sales following an anticipated decline in sales of its Lagevrio (molnupiravir) coronavirus (COVID-19) treatment.  The drugmaker also raised and narrowed its guidance for full-year 2023 sales.

Merck beats 1Q expectations as Keytruda gains offset Lagevrio decline

Caterpillar

Honeywell

The Dow looked poised for a sizable lift on Thursday morning. Merck and Honeywell released solid financial results that helped boost the Dow.

2 of These 3 Stocks Are Lifting the Dow, but 1 Is Holding It Back

Merck is looking to buy clinical stage biotech Prometheus Biosciences for $10.8 billion. The deal could bolster Merck's immunology portfolio with a potential blockbuster of an asset.

Merck Makes a Bold Move That Could Transform Its Business

Merck (MRK) came out with quarterly earnings of $1.40 per share, beating the Zacks Consensus Estimate of $1.34 per share. This compares to earnings of $2.14 per share a year ago.

Merck (MRK) Surpasses Q1 Earnings and Revenue Estimates

Merck & Co. Inc.'s stock MRK, -2.66% rose 2% premarket Thursday, after the company posted better-than-expected first-quarter earnings and offered guidance that topped estimates. Rahway, N.J.

Merck stock pops premarket after Q1 earnings beat

Merck reported first-quarter results that topped Wall Street's expectations. Still, revenue fell 9% year over year due to a steep drop in sales of Covid antiviral treatment molnupiravir.

Merck results beat expectations despite a big drop in sales of Covid antiviral treatment

Merck topped first-quarter forecasts Thursday thanks to Keytruda and Gardasil. The results could give Merck stock a much-needed boost.

Will Merck's Earnings Beat Give The Pharma Stock A Sorely Needed Boost?

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces First-Quarter 2023 Financial Results.

Merck Announces First-Quarter 2023 Financial Results

Advance Auto Parts

Ford Motor Company

Altria

Kellogg

ONEOK

PepsiCo

The Schwab US Divided Equity ETF (NYSEARCA: SCHD ) offers a basket of the best dividend stocks for investors. It's also a standout among top ETFs, having run from $25.50 in 2011 to a peak of $80 last year.

The 7 Best Stocks From Schwab's Dividend ETF

AbbVie

Bristol-Myers

Gilead Sciences

Eli Lilly

Let's look at the five biotech/pharma companies slated to release quarterly results on Apr 27.

Drug/Biotech Stocks' Q1 Earnings Due Apr 27: LLY, ABBV & More

The company needs combinations to extend Keytruda sales after patent expires.

Merck Keeps Striking Out on Expanding Its Cancer-Drug Juggernaut

We expect MRK stock to trade higher, with its revenue and earnings expected to be above the street estimates.

Earnings Beat In The Cards For Merck Stock?

American Airlines

In Tuesday morning trading, the Dow Jones industrials were down 0.23%, the S&P 500 down 0.71% and the Nasdaq 0.9% lower.

Earnings Previews: AbbVie, Altria, American Airlines, Merck

Alnylam Pharmaceuticals

Neurocrine Biosciences

As 2023 unfolds, the pharmaceutical space is blossoming with new opportunities, sparking curiosity for those looking to buy some pharma stocks. With the iShares Biotechnology ETF (NASDAQ: IBB ) ticking upward, for the most part, this year, investors who dive into pharma stocks need to capitalize on the sector's positive momentum.

3 Pharma Stocks That Could See a Surge in Demand in 2023

DexCom

Intuitive Surgical

SPDR S&P Regional Banking ETF

Invesco QQQ

Though the medium-term trend remains intact for tech, some subtle signs of weakness are appearing beneath the surface. Andrew Rocco breaks it down.

Sell the News? 5 Reasons Tech May Pullback

Stocks This Week: Buy Merck

Prometheus Biosciences

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Prometheus Biosciences, Inc. (NasdaqGS: RXDX) to Merck & Co., Inc. (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Prometheus will receive $200.00 in cash for each share of Prometheus that they own.

PROMETHEUS BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prometheus Biosciences, Inc. - RXDX

Merck (known as MSD outside the United States and Canada) and Prometheus Biosciences recently announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to buy Prometheus for $200 per share in cash for a total equity value of approximately $10.8 billion.

Why Merck Is Buying Prometheus Biosciences For About $10.8 Billion

Accenture Plc

Automatic Data Processing

Applied Materials

ASML Hld

Best Buy

Blackrock Inc

Cisco Systems

Fastenal

Ferguson Enterprises Inc

Garmin

Home Depot

Infosys

KLA-Tencor

Lockheed Martin

Lowe's

Lam Research

Mastercard

Monolithic Power Systems

Paychex

Rollins

Snap-on

Skyworks Solutions

T. Rowe Price Group

The 4-factor dividend growth portfolio was launched on November 1st, 2022, and despite a poor start to April the long term return is still attractive. The portfolio outperformed the S&P 500 Total Return by 29 bps during the month of March.

4-Factor Dividend Growth Portfolio - Sour Month

Ramping up its immunology pipeline with Prometheus Biosciences could help it move beyond Keytruda's eventual loss of exclusivity. Even so, the drugmaker faces several key challenges in this highly competitive space.

Is Merck Stock a Screaming Buy After This $11 Billion Acquisition?

GlaxoSmithKline

Biopharmaceutical companies are getting stock price lifts this week after two big deals in the space signal that M&A appetite is ripe. On Tuesday, GSK PLC (LSE:GSK, NYSE:GSK) revealed it has paid around $2 billion for Bellus Health (TSX:BLU), a Canada-based, late-stage biopharmaceutical company which specialises in respiratory treatments.

GSK, Merck deals show appetite is ripe for biopharmaceutical M&A

Roivant Sciences Ltd

Roivant Sciences shares took off on the news that Merck is acquiring Prometheus Biosciences in a $10.8 billion deal as investors placed their bets on which of the two companies could be first to bring to market their promising bowel disease drug candidate.   The acquisition adds Prometheus' monoclonal antibody treatment PRA023 being developed for ulcerative colitis (UC), Crohn's disease, and systematic sclerosis-associated interstitial lung disease to Merck's drug pipeline.

Roivant Sciences shares spike on Merck-Prometheus Biosciences deal

News for Merck Stock (MRK)